Asset profile
luveltamab tazevibulin
Antibody–drug conjugate
Evidence outlook
Phase 2/3 study terminated, no active studies registered
The furthest-phase study registered for this program (NCT05870748) was terminated, and no study is currently active on the registry. No evidence signal is assigned from a stopped study. Check the registry record for the sponsor's stated reason.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Competitive landscape
12 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 12 same-indication; 7 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Luveltamab Tazevibulin: this drug | Phase 2/3 | Antibody–drug conjugate | — | ||
| Avutometinib | Approved | Small molecule | RAF/MEK, MEK1/2 and RAF (CRAF, BRAF) | ||
| Defactinib | Approved | Small molecule | FAK | ||
| Niraparib | Approved | Small molecule | PARP1/2 | ||
| Relacorilant (Lifyorli) | Approved | Small molecule | Glucocorticoid receptor | ||
| INCB123667 | Phase 3 | Small molecule | — | ||
| Olvimulogene Nanivacirepvec | Phase 3 | Oncolytic Virus | No discrete molecular target | ||
| Rina-S | Phase 3 | Small molecule | Folate receptor alpha (FRα) | ||
| Birinapant | Phase 2 | — | — | ||
| Stenoparib | Phase 2 | Small molecule | — | ||
| COM701 | Phase 1 | Small molecule | — | ||
| IDE-161 | Phase 1 | Small molecule | PARG | ||
| XmAb541 | Phase 1 | Multispecific antibody | — |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.